Revolutionizing care for rare genitourinary tumours
暂无分享，去创建一个
[1] Siraj M. Ali,et al. Targetable gene fusions and aberrations in genitourinary oncology , 2020, Nature Reviews Urology.
[2] U. Capitanio,et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. , 2019, European urology.
[3] Eva Ardanaz,et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. , 2017, The Lancet. Oncology.
[4] Jonathan I. Epstein,et al. WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .
[5] N. Clarke,et al. Should centralized histopathological review in penile cancer be the global standard? , 2013, BJU international.
[6] J. Coindre,et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] G. Gatta,et al. Rare cancers are not so rare: the rare cancer burden in Europe. , 2011, European journal of cancer.